Immunogen Inc (NASDAQ:IMGN): Institutional Investor Sentiment Up to 1.29

ImmunoGen, Inc. (NASDAQ:IMGN) Logo

Sentiment for Immunogen Inc (NASDAQ:IMGN)

Immunogen Inc (NASDAQ:IMGN) institutional sentiment increased to 1.29 in 2019 Q1. Its up 0.22, from 1.07 in 2018Q4. The ratio is more positive, as 81 active investment managers increased or opened new equity positions, while 63 decreased and sold stock positions in Immunogen Inc. The active investment managers in our partner’s database now have: 113.69 million shares, down from 119.32 million shares in 2018Q4. Also, the number of active investment managers holding Immunogen Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 22 Reduced: 41 Increased: 50 New Position: 31.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company has market cap of $412.18 million. The firm develops its products using its antibody-drug conjugate technology. It currently has negative earnings. The companyÂ’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML.

The stock decreased 2.83% or $0.08 during the last trading session, reaching $2.75. About 1.10 million shares traded. ImmunoGen, Inc. (NASDAQ:IMGN) has declined 76.42% since August 15, 2018 and is downtrending. It has underperformed by 76.42% the S&P500.

Redmile Group Llc holds 1.04% of its portfolio in ImmunoGen, Inc. for 13.06 million shares. Qvt Financial Lp owns 1.38 million shares or 0.87% of their US portfolio. Moreover, Fernwood Investment Management Llc has 0.27% invested in the company for 187,000 shares. The California-based Endurant Capital Management Lp has invested 0.2% in the stock. Birchview Capital Lp, a Vermont-based fund reported 90,000 shares.

ImmunoGen, Inc. (NASDAQ:IMGN) Ratings Coverage

Ratings analysis reveals 50% of ImmunoGen’s analysts are positive. Out of 6 Wall Street analysts rating ImmunoGen, 3 give it “Buy”, 0 “Sell” rating, while 3 recommend “Hold”. The lowest target is $2.5 while the high is $12. The stock’s average target of $5.08 is 84.73% above today’s ($2.75) share price. IMGN was included in 13 notes of analysts from March 1, 2019. Guggenheim maintained the shares of IMGN in report on Friday, March 1 with “Buy” rating. H.C. Wainwright downgraded ImmunoGen, Inc. (NASDAQ:IMGN) rating on Monday, March 4. H.C. Wainwright has “Neutral” rating and $3.5 target. Canaccord Genuity maintained ImmunoGen, Inc. (NASDAQ:IMGN) on Friday, March 1 with “Buy” rating. On Friday, March 1 the stock rating was downgraded by Piper Jaffray to “Hold”. Jefferies downgraded the shares of IMGN in report on Friday, March 1 to “Hold” rating. RBC Capital Markets maintained the shares of IMGN in report on Monday, March 4 with “Buy” rating.

More notable recent ImmunoGen, Inc. (NASDAQ:IMGN) news were published by: which released: “ImmunoGen, Inc. (NASDAQ:IMGN): What Are The Future Prospects? – Yahoo Finance” on May 02, 2019, also with their article: “ImmunoGen Q4 2018 Earnings Preview – Seeking Alpha” published on February 07, 2019, published: “After Hours Most Active for Jul 5, 2019 : LC, IMGN, QQQ, SNAP, AVP, LXP, ESV, INTC, XNET, FOLD, CL, AAXJ – Nasdaq” on July 05, 2019. More interesting news about ImmunoGen, Inc. (NASDAQ:IMGN) were released by: and their article: “ImmunoGen, Inc. to Host Earnings Call – Yahoo Finance” published on August 02, 2019 as well as‘s news article titled: “What You’ll Want to Know About ImmunoGen’s Q2 Results – Yahoo Finance” with publication date: August 02, 2019.

ImmunoGen, Inc. (NASDAQ:IMGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.